Daniel Liebman, MD, MBA
Dr. Daniel Liebman graduated summa cum laude from Brandeis University with degrees in Health Science & Policy and American Studies. At Brandeis, he received the Presidential Scholarship and the Gila Prize for Excellence in American Studies, and was elected into the Phi Beta Kappa Honor Society. He went on to earn his MD from Harvard Medical School, as well as his MBA with second-year honors from Harvard Business School. As a medical student, Dr. Liebman studied digital design thinking and diffusion of ophthalmic innovation into clinical practice under the mentorship of James Chodosh, MD, MPH, Edith Ives Cogan Professor of Ophthalmology at Harvard Medical School. This work was published in Ophthalmology. He also worked with former Harvard Ophthalmology faculty member Carolyn Kloek, MD, to quantify the learning curve for cataract surgery, and was invited to present his findings to a national audience of ophthalmology program directors in a podium presentation at Association of University Professors of Ophthalmology. This work was subsequently published in the Journal of Cataract and Refractive Surgery.
In addition to his work in ophthalmology, Dr. Liebman has a longstanding commitment to health policy, innovation, and public health leadership, with past roles spanning government, academia, advocacy, nonprofits, and the private sector. He has worked as a full-time health policy analyst at the Harvard School of Public Health, interned with the United States Senate, worked as a strategic consultant for early stage biomedical companies, and conducted research on institutional-level innovation and value-based care as a Massachusetts General Hospital Foster Scholar. He was elected chairman of the Massachusetts Medical Society’s Medical Student Section and has served as a Massachusetts delegate to the American Medical Association. His writing on health policy and innovation has been featured in numerous academic and mass media outlets, including the Los Angeles Times, Slate Magazine, Health Affairs, and the New York Times Upshot.